Janus Henderson Backs Biotech Mergers Amid Akeso-Merck Drug Data Conflict
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Janus Henderson is supporting biotech reverse mergers. Separately, dueling clinical findings have emerged between Akeso's drug ivonescimab and a rival Merck medication. Summit Therapeutics and Akeso recently revealed new findings regarding this drug, which impressed Wall Street.
From biopharmadive.com
Why it matters
The emergence of conflicting clinical data between Akeso and Merck could affect the competitive position of both companies. Janus Henderson's investment in biotech reverse mergers indicates continued financial interest in the pharmaceutical sector.
From biopharmadive.com
Who's involved
- AkesoChinese Biopharmaceutical Company involved in drug development and co-development.
- Janus HendersonInvestment firm backing biotech reverse mergers and holding an investment relationship with Akeso.
- MerckPublic company competing with Akeso in the market and involved in joint vaccine development.
- Summit TherapeuticsBiopharmaceutical company relying on Akeso's core IP for the co-development of ivonescimab.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AkesoSpeculative
Might see market price changes due to positive drug data emergence.
Keep exploring
The entities involved
-
Akeso
Chinese Biopharmaceutical Company
Nothing else this week.
-
Janus Henderson
British-Australian investment firm
Nothing else this week.
-
Merck
public company in Indonesia